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ABSTRACT
Adenovirus virus-associated (VA) RNAs are pro-
cessed to functional viral miRNAs or mivaRNAs.
mivaRNAs are important for virus production,
suggesting that they may target cellular or viral
genes that affect the virus cell cycle. To look for
cellular targets of mivaRNAs, we first iden-
tified genes downregulated in the presence of VA
RNAs by microarray analysis. These genes were
then screened for mivaRNA target sites using
several bioinformatic tools. The combination
of microarray analysis and bioinformatics allowed
us to select the splicing and translation
regulator TIA-1 as a putative mivaRNA target.
We show that TIA-1 is downregulated at mRNA
and protein levels in infected cells expressing
functional mivaRNAs and in transfected cells that
express mivaRNAI-138, one of the most abundant
adenoviral miRNAs. Also, reporter assays show
that TIA-1 is downregulated directly by mivaRNAI-
138. To determine whether mivaRNAs could
target other cellular genes we analyzed 50 addi-
tional putative targets. Thirty of them were
downregulated in infected or transfected cells
expressing mivaRNAs. Some of these genes are
important for cell growth, transcription, RNA metab-
olism and DNA repair. We believe that a mivaRNA-
mediated fine tune of the expression of some of
these genes could be important in adenovirus cell
cycle.
INTRODUCTION
RNA interference (RNAi) is a posttranscriptional gene
silencing process that aﬀects from Saccharomyces pombe
to humans. RNAi-mediated regulation of gene expression
is achieved by inducing gene deletion, DNA heterochro-
matinization, mRNA decay or translation inhibition (1).
Several small non-coding RNAs have been described that
guide the RNAi machinery in controlling the expression of
speciﬁc genes. In mammals, small RNAs include small
interfering RNAs (siRNAs) and microRNAs (miRNAs)
(2). siRNAs, with perfect complementarity to their
targets, activate RNAi-mediated cleavage of the target
mRNAs, while miRNAs generally induce RNA decay
and/or translation inhibition of target genes (3–6).
MicroRNAs (miRNAs) are  22-nt long RNAs pro-
cessed from long primary transcripts, called pri-
miRNAs. pri-miRNAs are cleaved in the nucleus by an
RNAse III called Drosha, into imperfectly pairing stem-
loop precursors of  70nt called pre-miRNAs (1,7). The
pre-miRNAs are then exported by Exportin 5 (Exp5) to
the cytoplasm, where Dicer processing renders mature
double-stranded miRNAs that interact with the RNA-
induced silencing complex (RISC) (1,8,9). The antisense
strand of the miRNA must be incorporated into RISC,
to guide the complex to the 30UTR of the target gene (9).
There, recognition of only 6nt that base pair with the seed
sequence of the miRNA are enough to induce functional
inhibition of the target gene (10).
miRNA-regulated genes are not easy to identify.
Searching for mRNAs that contain a given 6-nt long
sequence in their 30UTR, retrieves few real targets
scattered among thousands of other mRNAs.
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real miRNA targets have incorporated into their
algorithms other features that may inﬂuence miRNA tar-
geting. These beneﬁt (i) AU-rich sequences near the target,
which may be an indirect measurement for target accessi-
bility, (ii) proximity of the target to residues pairing to
miRNA nucleotides 13–16, (iii) proximity of the target
to other miRNA targets which may act cooperatively
and (iv) target location away from the center of long
30UTRs and relatively close to the stop codon (11).
Biochemical approaches have also been used to identiﬁed
miRNA targets. As miRNAs induce RNA decay and/or
translation inhibition of target genes, both proteomics
and genomics have been employed (3,4,6). Comparison
of the proteome between control cells and cells expres-
sing a given miRNA, should result in identiﬁcation
of proteins whose expression is downregulated by the
miRNA. Microarray technology allows analysis of
complete genomes and can be used for identiﬁcation of
all mRNAs with target sequences that decrease in the
presence of a given miRNA. However, this approach
does not identify targets aﬀected exclusively by translation
inhibition.
It has been calculated that RNAi controls the expres-
sion of 30% of human genes, some involved in develop-
ment, diﬀerentiation, apoptosis and proliferation (10,12).
Moreover, a clear connection between cancer and RNAi
has been shown (13). In plant and insect cells, RNAi
also works as an alternative immune mechanism against
viral infections (14). Several mammalian viruses are
also inhibited by siRNAs or certain cellular miRNAs,
suggesting that RNAi could play an antiviral role also
in vertebrates (15,16). Plant viruses have evolved to
escape antiviral RNAi with the development of silencing
suppressors. Several animal viruses have been also
described as encoding silencing suppressors, such as
PFV-1 Tas, HIV Tat, inﬂuenza NS1, vaccinia E3L,
Ebola VP35, HCV core and adenovirus virus-associated
(VA) RNA (15,17–22). Controversy exists because viruses
have also been described as using the cellular silencing
machinery to control gene expression. Thus, viral
miRNAs that could regulate expression of both host and
viral genes have been described in several viruses
(17,23–27). Surprisingly, adenovirus VA RNAs can act
both as silencing suppressors by inhibiting Dicer and
RISC and as precursors of viral miRNAs (17,21,23,28).
Most human adenovirus, including serotypes 2 and 5,
express two VA RNAs, VAI and VAII (29). These VA
RNAs are non-coding polymerase III-transcribed
 160-nt long RNAs that fold into a dsRNA with a well-
conserved structure (29). VA RNAs are very abundant
during viral infection. VA RNAI accumulates to 10
8
molecules per cell (30), and therefore, may saturate or
block several cellular VA interacting factors. After
nuclear transcription, VA RNAs have been described to
saturate Exp5 on their way to the cytoplasm (21). There,
VAI is involved in the blockade of RNA-dependent
protein kinase (PKR), an interferon-inducible serine-
threonine protein kinase activated in infected cells as
part of the antiviral response (31). Also, as VA RNAs
and pre-miRNAs have a similar structure, VA RNAs
bind and block Dicer (17,21). However, 2–5% of the VA
RNAs can be processed by Dicer in their terminal stem to
adenoviral miRNAs named svaRNAs or mivaRNAs
(17,23). Even if Dicer processing is not eﬃcient, over 10
6
mivaRNAs are produced that can bind the RISC complex
(17,23,28). mivaRNAs with VA RNA 30-terminal
sequences are preferentially incorporated into RISC
(17,23,28). The most abundant are two mivaRNAs
from VAI, where Dicer may cut at nucleotide 137 or 138
(mivaRNAI-137, mivaRNAI-138), and a single mivaRNA
from VAII, where Dicer most favorably cuts at position
138 (mivaRNAII-138) (28). Analysis of RISC-bound
miRNAs in adenovirus-infected cells have showed that
80% correspond to mivaRNAs, indicating saturation of
RISC and decrease in regulation by cellular miRNAs in
infected cells (28). However, RISC-bound mivaRNAs can
inhibit the expression of genes with complementary
sequences (23,28). Also, inhibition of mivaRNAI with
antagomirs aﬀects eﬃcient adenovirus production, sug-
gesting that mivaRNAs could regulate the expression of
cellular or viral genes that may aﬀect virus viability (23).
We believe that mivaRNAs may function as viral
miRNAs, as we have not found cellular or viral genes
with perfect complementary sequences to mivaRNAs.
The combination of bioinformatics and genomics has
allowed us to identify several putative mivaRNA targets.
Thirty-one out of the 50 genes analyzed are
downregulated in cells expressing mivaRNAs. Further,
we have validated TIA-1 as a direct target of
mivaRNAI-138.
MATERIALS AND METHODS
Cell lines and viruses
Human 293 and HeLa cells were obtained from the
ATCC. All cell lines were cultured in DMEM medium,
supplemented with 10% FBS, 1% penicillin–streptomycin
and 2mM L-glutamine. Cell lines were cultured at 37 Ci n
a5 %C O 2 atmosphere. All cell culture reagents were
obtained from Gibco BRL/Life Technologies. Plasmids
were transfected using calcium phosphate as described
(32). Transfection eﬃciency was >90%. Transfection
with 20-O-methyl oligonucleotides (Sigma) was performed
using Lipofectamine 2000 (Invitrogen) following the
recommendations of the supplier as described (23). In
brief, 100pmol of oligo were added to 3.5 10
5 cells in
1ml of Opti-MEM (Gibco). 20-O-methyl oligonucleotides
used were 2omeMut (CGACGUCAGACAACGGGGGA
GCGCUCCUUUU), and 2omeAS30 (AAAAGGAGCG
CUCCCCCGUUGUCUGACGUCG).
Adenoviruses were ampliﬁed in 293 cells, puriﬁed by
double cesium chloride gradient ultra-centrifugation and
desalted in a G50 sephadex column (33). The Adenovirus
titer was calculated with AdenoX rapid titer kit (BD
Biosciences) or by limiting dilution. 293 cells were
infected in DMEM 2% FBS with 1 moi (multiplicity of
infection) of wild-type adenovirus type 5, or mutant VA
(34). Transfected cells were infected one day after
transfection and analyzed when indicated.
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pAdvantage (Promega) contains VAI and VAII genes
from adenovirus type 2 with their own promoters.
pSuper (35) plasmid is widely used to express shRNAs
from a H1 promoter. To construct pVAI, VAI sequences
were ampliﬁed with oligo pSUPVAI50 (GCGCGA
GATCTCCCGGGCACTCTTCCGTGGTCTGG) and
pSUPVAI30 (GCGCGAAGCTTTCCAAAAAGGAGC
GCTCCCCCGTT). The ampliﬁed fragment was digested
with BglII and HindIII, gel puriﬁed and cloned in the
same sites of pSuper. pmivaRNAI-138 was constructed
by cloning the hybridized oligonucleotides shVAI-150
(GATCCCCGGGCACTCTTCCGTGGTCTTTCAAGA
GAGACAACGGGGGAGCGCTCCTTTTTGGAAA)
and shVAI-130 (AGCTTTTCCAAAAAGGAGCGCTCC
CCCGTTGTCTCTCTTGAAAGACCACGGAAGAGT
GCCCGGG) into the BglII and HindIII sites of pSuper.
pHA-TIA-1 was obtained from Juan Valca ´ rcel and
expresses TIA-1 protein fused to a HA peptide. pGL3-
Promoter (Promega) expressing Fireﬂy luciferase was
used as a transfection control. pRL-SV40 (Promega) was
used to construct the plasmids that express TIA-1 target
sequences in the 30UTR of renilla mRNA. Proper
oligonucleotide sequences were cloned in the Xba I–Not
I site of pRL-SV40 to obtain pRL-TIA-1 (CAGGGA
GUGUAGUAAAGCCGUUGUUUACUUAAAG) and
pRL-TIA-1Mut (CAGGGAGUGUAGUAAAGGGCA
ACAUUACUUAAAG). Positive clones were veriﬁed by
DNA sequencing (ABI Prism 310 genetic analyzer from
Perkin-Elmer).
Protein analysis
Renilla and ﬁreﬂy luciferase activity was quantiﬁed using
the Dual Luciferase System (Promega) as previously
described (36) in a Berthold Luminometer (Lumat LB
9507). Western blots were hybridized to TIA-1 (ML-29)
monoclonal antibody (a kind gift from J. Valca ´ rcel), or
goat anti-TIA-1 (C-20, Santa Cruz) diluted 1:1000.
Secondary antibodies were anti-mouse, or anti-goat
coupled to peroxidase diluted 1:5000 (Sigma). Western
blots were developed with ECL (Perkin-Elmer).
Preparation and analysis of RNA
Total RNA was puriﬁed using guanidium thiocyanate as
described (37) or the RNeasy kit (Qiagen) following the
recommendations of the supplier. Quantitative RT–PCRs
were performed with the protocol and oligonucleotides
recommended by Applied Biosystems. To detect TIA-1
we used Hs 00234977_m1 and Hs 00254561_m1, and Hs
99999905_m1 for GAPDH, used as a control. Primers
used for the other genes analyzed are listed in Table 1.
Microarray analysis
RNA isolated from cells mock transfected or transfected
with pAdvantage and collected 3 days posttransfection
was processed as recommended by Aﬀymetrix. The
aﬀymetrix Test 2 Array was used to determine the
quality of the RNA. After column cleanup of the RNA
with Qiagen Rneasy, cDNA was synthesized by using an
oligo(dT) primer attached to a sequence of the
T7 promoter region. This cDNA was then used to
perform in vitro transcription with bacteriophage T7
RNA polymerase and biotin-labeled nucleotides from
the IVT Labeling kit (Aﬀymetrix). Labeled RNA was
puriﬁed, quantiﬁed spectrophotometrically, fragmented
and hybridized to the Aﬀymetrix Human Genome U133
Plus 2.0. The arrays were washed, stained, and scanned
by using a confocal scanner (Aﬀymetrix). Finally, the
results were analyzed with GeneChip Operating
Software (GCOS, Aﬀymetrix).
Both background correction and normalization were
carried out using RMA (Robust Multichip Average) algo-
rithm (38). We ﬁrst restricted the data analysis to probe
sets in which percentage of present calls in at least one
of the experimental conditions was >20% (Aﬀymetrix
Microarray suite user guide, version 5). This ﬁlter
reduced the number of targets included in the experiment
to 39284 probe sets, which were considered for the statis-
tical analysis. The selection of those genes diﬀerentially
expressed in cells transfected with pAdvantage with
respect to the mock transfected cells was performed
using a t-test statistics (39). A cut-oﬀ P-value according
to a FDR (40) of 5% was established as the selection cri-
terion, resulting in a set of 1384 probe sets.
Functional categories enriched by Gene Ontology (GO)
analysis were detected using a standard hypergeometric
test (41). The results were complemented with Ingenuity
Pathway Analysis (Ingenuity Systems, www.ingenuity
.com), as this database includes manually curated and
fully traceable data retrieved from literature. A proximal
promoter analysis of the selected genes was performed
with FactorY. This web application facilitates the identi-
ﬁcation of common regulatory mechanisms involved in
the transcriptional control of co-expressed genes (42).
Brieﬂy, FactorY calculates the enrichment of transcription
factor binding sites from the public versions of Jaspar (43)
and Transfac (44) databases with a hypergeometric distri-
bution. The proximal promoter of each diﬀerentially
expressed gene is deﬁned as 1000bp upstream of the tran-
scription start site and has been extracted from Ensembl
database release 35 (45).
Sequence analysis for microRNA target prediction
MotifLocator can be used to screen DNA sequences with
precompiled motifs (46). Motifs described in Figure 2C
were scanned with MotifLocator against the 30UTR
sequence of each diﬀerentially expressed gene extracted
from the Ensembl database release 35. Putative targets
for adenoviral miRNAs and putative cellular miRNAs
that may bind TIA-1 mRNA were searched for using
TargetScan, MiRanda and PicTar (10,47,48). Targets for
adenoviral miRNAs obtained from TargetScan were
combined to diﬀerentially expressed genes identiﬁed in
the VA microarray analysis. As a result, putative
microRNA target genes with altered expression were
identiﬁed.
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High-throughput analysis of genes altered upon
expression of VA RNAs
Several approaches were used to identify cellular targets
of mivaRNAs. As miRNAs induce mRNA decay and/or
translational repression of target mRNAs, we ﬁrst looked
for proteins decreased in the presence of mivaRNAs.
Thus, we compared the proteome of mock-transfected
cells and cells transfected for three days with
pAdvantage (pVA), which expresses RNA VAI and
VAII. Several proteins were identiﬁed by mass-
spectrometry that were decreased or increased in the
presence of VA RNA (data not shown). However, none
of the genes that encode for these proteins contained
mivaRNA seed complementary sequences, neither in
their 30UTR nor in their coding region (data not
shown). Therefore, we decided to use a transcriptomic
approach to identify mivaRNA targets. RNA isolated
from mock-transfected HeLa cells or HeLa cells
transfected for three days with pVA, was hybridized to
HG-U133-Plus2 microarrays (Figure 1A). The experiment
was done three times to increase the signiﬁcance of the
statistical analysis (see Materials and methods section
for details). The analysis of the microarrays indicated
that 39284 probes showed expression out of the 54675
probes spotted in the array. Altered expression was signif-
icant for 4095 probes (P<0.01) but a more stringent sta-
tistical analysis showed signiﬁcant diﬀerences in 1384
probes (FDR<0.05). We found that 730 probes, which
correspond to 637 genes, were upregulated in
pVA-transfected cells (Figure 1A; Supplementary Table
S1). 654 probes, which correspond to 462 genes, were
downregulated in the presence of pVA (Supplementary
Table S1).
Upregulated genes showed a clear signature of NFkß
activation (Supplementary Figure S1). We used FactorY
to analyze the promoters of all upregulated genes and
identify common transcription factors that regulate the
expression of many of these genes. The results showed a
signiﬁcant enrichment of genes activated by NFkß. We
believe that polymerase III-transcribed VA RNA, with
3p-50-ends, activated RIG-I and therefore NFkß. NFkß
activation leads to an increase of inﬂammatory cytokines
such as IL6 and IL1, both found in the list of upregulated
genes. We scanned upregulated genes with Ingenuity to
ﬁnd interaction networks. This is done by searching for
links between genes into a database of curated informa-
tion derived from the literature. This analysis showed that
the network with the highest score contained NFkß-
related genes (Supplementary Figure S1). Functional
analysis of downregulated genes showed a single
network exclusively related to RNA metabolism. Thus,
50 genes out of the 462 downregulated genes are
involved in splicing, translation or encode for RNA
binding proteins (Supplementary Table S2). Only few
downregulated genes function in RNA polyadenylation,
stability or transport. Besides, the transcription factor
binding sites of Ets-1 and Elk were found statistically
enriched upon FactorY analysis of downregulated genes.
Indeed, Ets-1 and Elk were downregulated in the presence
of pVA and this may account for the decreased expression
of several genes.
Identiﬁcation of putative mivaRNA-targeted genes
altered in the presence of VA RNAs
VAI RNA is processed at the terminal stem to 50 and
30mivaRNAIs that could inhibit the expression of target
genes (Figure 1B). To search for putative targets of these
mivaRNAs, we performed a bioinformatic analysis using
TargetScan (23). TargetScan is an algorithm that predicts
targets of miRNAs by searching for conserved sites that
match the seed region of a given miRNA. TargetScan
analysis with 50and 30 mivaRNAIs as input sequences
yielded 863 and 198 putative targets, respectively. Then,
we looked for genes identiﬁed by TargetScan that were
also downregulated in the microarray analysis. When we
compared all the genes altered in the microarray analysis
with the genes identiﬁed by TargetScan with the
50mivaRNAI, we found 15 common genes downregulated,
but also 30 common genes upregulated (Figure 2A, left).
This result is discouraging, as it has been described in
the analysis of other microarrays that study the eﬀect of
miRNAs, that few upregulated genes with target
sequence should be found. This eﬀect has been described
as ‘antitarget signature’. In fact, the antitarget eﬀect was
found when we compared the genes altered in the
microarray analysis with the genes identiﬁed by
TargetScan with the 30mivaRNAI. In this case, we found
23 common genes downregulated and only 1 common
gene upregulated (Figure 2A, right). This result leads us
Figure 1. (A) Work ﬂow of the microarray analysis. RNA isolated
from triplicates of HeLa cells mock transfected or transfected with
pVA was hybridized to Aﬀymetrix HG-U133-Plus2 microarrays con-
taining 54675 probes. Out of the 39284 probes that showed expression,
4095 showed diﬀerent expression between mock and pVA transfected
cells. Expression diﬀerences were signiﬁcant for 1384 probes which cor-
responded to 637 upregulated genes (730 probes) and 462 down-
regulated genes (654 probes) in the presence of VA RNAs.
(B). Schematic of VAI RNA processing to viral miRNAs. The
terminal nucleotide sequence of VA RNAI processed to viral
miRNAs is indicated. The structure of the remaining VA RNAI is
depicted with a black line. VA RNAI is processed to a minor
50 miRNA and two major 30 miRNAs (mivaRNAI-137 and -138).
The cleavage site for each miRNA is indicated with an arrow.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 753to propose that the 30mivaRNAI could inhibit gene
expression at the level of mRNA stability of one or
several of these 23 common genes.
TargetScan searches for seed complementary sequences
in conserved regions. However, adenovirus is non-
replicative in rodents, so sequence conservation should
not be taken into consideration to deﬁne putative targets
of mivaRNAs. Thus, we decided to use Motif Locator,
which searches for a given sequence in all the genes
included in a database. Motif Locator was used to
identify seed complementary target sequences in the
30UTR of all the genes with altered expression in the
microarray analysis. The number of VA RNA upregulated
genes with seed complementary sequences was calculated
to gauge the speciﬁcity of the analysis. We deﬁned the best
antitarget eﬀect as the highest ratio of the relative number
of seeds in downregulated genes versus the relative
number of seeds in upregulated genes. Three diﬀerent
sequences were used as input for the Motif Locator
analysis. These sequences correspond to the seeds of the
two major 30mivaRNAs of VAI (137 and 138) (Figure 1B)
and the major 30mivaRNA of VAII (Figure 2B). Also,
seeds contained nucleotides 2–7 or 2–8 of the mivaRNA
and may have an Adenine at the end of the sequence
(Figure 2C) (10). The results of these analyses show
that in all cases the number of seed complementary
sequences in downregulated genes is higher than in
upregulated genes, indicating a certain antitarget eﬀect
Figure 2. Analysis of genes with putative mivaRNA target sequences whose expression is altered in the presence of VA RNAs. (A) Color code of the
VA RNA microarray expression of the genes identiﬁed by TargetScan using VAI miRNAs as input sequences. Expression of the genes listed at the
bottom of the table was detected with the indicated probes. The probes were spotted on microarrays hybridized with RNA isolated from mock
transfected cells (pMock1 to 3) or cells transfected with pVA (pVA1-3), as indicated to the left. Expression levels range from red (higher expression)
to green (lower expression), as gradiented to the right. The genes are upregulated (Up) or downregulated in pVA transfected cells, as indicated at the
top of the ﬁgure. The genes shown are also identiﬁed by TargetScan with 50mivaRNAI sequences (left) or 30 mivaRNAI-138 sequences (right).
(B) Summary of the analysis of 30mivaRNA seed-complementary sequences in the genes with altered expression in the VA RNA microarray.
The sequence, target seed-complementary sequence and relative abundance of major 30mivaRNAs from VAI and VAII are shown. The table also
indicates the number (n) and percentage (%) of genes with seed complementary sequences which are upregulated (up) or downregulated (down) in
the presence of VA RNAs. (C) Bar graph showing the percentage of genes with altered expression in the pVA microarray and with seed comple-
mentary sequences. Seeds chosen are either total or complementary to positions 2–7 or 2–8 of the seed with or without an extra A. Seed target
sequence from mivaRNAI-138, mivaRNAI-137 and mivaRNAII-138 is indicated at the top of the graphs. Plotted genes are either downregulated
(down) or upregulated (up) in the presence of VA RNA.
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increased when the analysis was performed with longer
seeds (Figure 2C). The best antitarget eﬀect was
obtained with the seed of the mivaRNAI-138. Analysis
with the other seeds identiﬁed a higher number of
putative targets, even if the GCU content of the three
sequences tested was almost identical (Figure 2B).
Analysis of TIA-1 mRNA as a mivaRNAI-138
putative target
A set of rules was deﬁned to choose a putative target of
mivaRNAs that could be studied further. We
concentrated on putative targets of mivaRNAI-138, as
they showed the best antitarget eﬀect (Figure 2B and
Figure 2C). Also, we decided to choose a VA RNA
downregulated gene that was also identiﬁed by
TargetScan. These conditions limited the possibilities to
23 genes. Finally, as VA RNA downregulated genes
showed a signiﬁcant increase for genes related to splicing
and translation (Supplementary Table S2), we arbitrarily
decided to choose the only candidate involved in both
processes. Thus, we decided to analyze the eﬀect of
mivaRNAI-138 in the expression of the T-cell intracellular
antigen 1 gene (TIA-1).
The putative target of the mivaRNAI-138 found in
TIA-1 mRNA fulﬁls several requirements to be considered
a good target (11). First, the target locates in the 30UTR
close to the stop codon of TIA-1 mRNA (Figure 3A).
Second, the target can base-pair to a seed of 7nt in the
mivaRNAI-138 and pairing can be extended to
nucleotides 12–20 (Figure 3A). Furthermore, the seed
complementary sequence is located between a region par-
ticularly enriched for A and U nucleotides (Figure 3A).
Finally, ClustalX analysis has shown that the target is
well-conserved in Pan troglodytes and the seed comple-
mentary sequence has a single C to U change in
Mus musculus, which could still lead to a G:U pairing
(Figure 3A).
The 30UTR of TIA-1 mRNA was scanned with PicTar,
TargetScan and miRanda, which predict miRNA targets.
These programs revealed that several cellular miRNAs
could bind to TIA-1 mRNA close to the putative
mivaRNAI-138 target site, so they could theoretically
act cooperatively (Figure 3B). These include hsa-miR-
892b, hsa-miR-339, hsa-miR-337-5p and several hsa-
miR-30 (Figure 3B; note that only one hsa-miR-30 is
shown). Interestingly, two cellular miRNAs, hsa-
miR337-5p and hsa-miR-30, could bind to adjacent seed
complementary sequences that could, probably, deﬁne an
accessible region targeted by mivaRNAI-138. We could
not ﬁnd any cellular human miRNA with the same seed
sequence as the mivaRNAI-138.
TIA-1 is downregulated in the presence of mivaRNAI-138
We wanted to validate the downregulation of TIA-1
mRNA upon VA RNA expression observed in the
microarray analysis. To this aim, we used diﬀerent
plasmids that express the mivaRNAI-138. The plasmids
chosen were pVA, pVAI, which only expresses VAI RNA
from a polymerase III histone promoter, and
pmivaRNAI-138, which uses the same promoter to
express a shRNA processed to accumulate the
Figure 3. Analysis of the putative miRNA target sequence in TIA-1 30UTR. (A) mivaRNAI-138 target sequence in TIA-1 mRNA. Human (hs) TIA-
13 0UTR sequence close to the stop codon (bold) is shown. Non-conserved nucleotides of the same sequence in chimpanzee (pt) and mice (mm) are
indicated. The putative binding showed between the mivaRNAI-138 and TIA-1 mRNA has been predicted by TargetScan. Base pairing is indicated
with a line and GU wobbles are connected with a colon. The seed target is highlighted in bold and underlined. (B and C) Target sequences in TIA-1
30UTR from cellular miRNAs. (B) TargetScan predicted binding between TIA-1 30UTR and hsa-miR-892b, hsa-miR-339, hsa-miR-30c and hsa-miR-
337-5p. (C) Seed complementary sequences to the miRNAs shown in (B) are boxed. mivaRNAI-138 seed binds to the seed target sequence of hsa-
miR-30 and hsa-miR-337-5p.
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ﬁrmed by primer extension in cells transfected with these
plasmids (Supplementary Figure S2). RNA isolated from
HeLa or 293 cells mock-transfected or transfected with
pVA, pVAI or pmivaRNAI-138, was also used to
perform quantitative RT–PCR analysis of TIA-1
mRNA. The result shows that TIA-1 mRNA is decreased
to similar levels in HeLa or 293 cells expressing VA
RNAs, only VAI RNA or solely the mivaRNAI-138
(Figure 4A and B).
TIA-1 mRNA levels were also evaluated in 293 cells
infected with wild-type adenovirus or an adenovirus
mutant that does not express VA RNAs. The quantitative
RT–PCR analysis of TIA-1 mRNA was evaluated at 6, 12,
24, 48 and 72 h postinfection (hpi). The results show that
similar levels of TIA-1 mRNA are observed in cells
infected with the adenovirus mutant or in cells infected
with wild-type adenovirus at early times postinfection
(Figure 4C). However, TIA-1 mRNA levels decrease in
cells infected with wild-type adenovirus for 48 or 72h,
whereas no changes were observed in cells infected with
the mutant adenovirus (Figure 4C).
Similar results are observed when TIA-1 protein is
evaluated by western blot analysis (Figure 5). TIA-1 is
decreased to similar levels in cells expressing VA RNAs,
VAI RNA or mivaRNAI-138 (Figure 5A). Quantiﬁcation
of diﬀerent experiments indicates that TIA-1 decreases
2-fold in the presence of mivaRNAI-138 (data not
shown). Two-fold is an expected miRNA-mediated repres-
sion. A similar decrease was observed in cells infected with
wild-type adenovirus for 24h, when, in our experimental
settings, the initiation of the late phase of adenovirus
infection occurs (Figure 5B). To determine whether
TIA-1 is also downregulated by mivaRNAI-138 in
adenovirus-infected cells, we blocked 30mivaRNAI
functionality with antagomirs. We found that TIA-1
expression is not altered in adeno-infected cells transfected
with an antagomir complementary to the mivaRNAI-138,
Figure 4. TIA-1 mRNA is downregulated in the presence of VA RNA. (A and B) TIA-1 mRNA is downregulated in cells transfected with pVA.
RNA was isolated from 293 (A) or HeLa (B) cells mock transfected or transfected with pVA, pVAI or pmivaRNAI-138. Then, GAPDH and TIA-1
mRNAs were quantiﬁed by RT–PCR and plotted for comparison. (C) TIA-1 mRNA is downregulated at late times postinfection with wild-type
adenovirus. The 293 cells were infected with wild-type (AdWT) or a VA mutant adenovirus and RNA was isolated at 6, 12, 24, 48 and 72hpi.
Quantitative RT–PCR was performed as indicated in (A). Error bars show standard deviations of three diﬀerent experiments. Asterisk highlights
signiﬁcant diﬀerences while ns indicates non-signiﬁcant diﬀerences.
Figure 5. TIA-1 protein is downregulated in the presence of VA RNA.
(A) TIA-1 protein is downregulated in cells transfected with pVA.
HeLa cells were transfected with control plasmids expressing a non-
related gene (pMock) or a non-related shRNA (pshMock) or with
pVA, pVAI or pmivaRNAI-138 plasmids. Extracts were collected at
48h posttransfection and TIA-1 and U2AF65, used as a loading
control, were evaluated by western blot analysis. (B) TIA-1 protein is
downregulated in cells infected with wild-type adenovirus with func-
tional 30mivaRNAIs. 293 cells were transfected with antagomiRs that
block 30mivaRNAI function (2OmeAS30) or with a mutant control
(2OmetMut). These cells were infected with AdWT at 24h
posttransfection. Untransfected cells were also infected or mock
infected, as a control. Extracts were collected at 24hpi and TIA-1
and U2AF65 proteins were analyzed as in (A).
756 Nucleic Acids Research, 2010,Vol. 38,No. 3while TIA-1 is decreased 40% in infected cells transfected
with a mutant antagomir (Figure 5B).
TIA-1 mRNA is targeted directly by 30mivaRNA
mivaRNAI-138 could downregulate TIA-1 expression
directly or indirectly, as a secondary eﬀect of
mivaRNAI-138 targeting a gene involved in TIA-1 expres-
sion. To discriminate between these two possibilities, we
performed a reporter assay. The putative target sequence
of mivaRNAI-138 in TIA-1 was cloned in the 30UTR of a
Renilla luciferase reporter (Figure 6A). A mutant version
in the seed-complementary sequence was also cloned as a
negative control (Figure 6A). Renilla luciferase activity
was measured in cells transfected with either of these
plasmids and a control plasmid or plasmids that
express VAI and VAII RNAs, only VAI or mivaRNAI-
138. A plasmid expressing Fireﬂy luciferase was also
co-transfected in all cases and Fireﬂy luciferase activity
was measured as a transfection control. The result shows
that mivaRNAI-138 expression decreases 2-fold Renilla
luciferase expression from the Renilla luciferase mRNA
with target sequences (Figure 6B). Renilla luciferase
expression from the construct that lacks a seed comple-
mentary sequence was not altered, suggesting that pairing
between the seed sequence of mivaRNAI-138 and the
target mRNA is required for inhibition. These results
allow us to suggest that TIA-1 has a target sequence
that could interact directly with mivaRNAI-138, which
could induce miRNA-mediated downregulation of TIA-
1 mRNA.
Several genes are downregulated in the presence of
mivaRNAs
The results obtained with TIA-1 were encouraging, as
TIA-1 was chosen arbitrarily from a list of 462 genes
downregulated in the VA RNA microarray. Thus, we
wondered whether the expression of other genes from
the same list could also be controlled by mivaRNAs.
Motif Scanner searches using the major adenoviral
mivaRNAs as input sequences, found seed com-
plementarity in the 30UTR of 305 genes out of the
462 downregulated in the VA RNA microarray
(Supplementary Table S3). We decided to study 50 of
these genes in more detail. We also analyzed as a
control SFRS1, which was found downregulated in the
VA RNA microarray but lacked seed complementarity
to major mivaRNAs. Out of the 50 genes chosen,
22 have good seed complementarity to mivaRNAI-138.
In fact, 14 of them were also identiﬁed by TargetScan.
We also included genes with good seed complementarity
(A+2-8, see Figure 2C) to mivaRNAI-137 (n=4)orto
mivaRNAII-138 (n=12). Twelve random genes of well-
known function were also chosen.
We decided to use quantitative RT–PCR as a simple
method to test whether the expression of these genes
decreases in cells expressing mivaRNAs. This technique
was able to detect expression of all genes except EIF2S2
and USP6, which were eliminated from the study. First,
we quantiﬁed RNA levels of the remaining 49 genes and
GAPDH, used as a control, in 293 cells infected for 12, 24,
48 or 72h with a moi of 1 of wild-type adenovirus (WT) or
the adenovirus mutant that does not express VA RNAs
(VA). The results were used to calculate the fold inhibi-
tion (FI) for each gene and time postinfection, deﬁned as
the ratio of the expression levels obtained in cells infected
with VA versus the levels in cells infected with WT
(Table 1). We consider that genes strongly inhibited
by VA RNA expression should show FI higher than 1.5
at 48hpi and higher than 2.0 at 72hpi. Sixteen genes
did not ﬁt these criteria. However, the FI of the remaining
33 genes ﬁt the criteria and their FI tended to increase
at later times postinfection. In these cases, expression
levels in VA-infected cells were higher than in WT
virus-infected cells, although the mRNA content
could actually decrease in the course of infection
(Figure 7A).
To test whether mivaRNAs were involved in the
observed inhibition of gene expression, we evaluated
RNA levels of the 49 genes in HeLa cells transfected
with pVA, pVAI, pmivaRNAI-138 or with a control
plasmid. The results are shown in Figure 7B and expressed
as FI in Table 1. Out of the 33 genes downregulated in
infected cells expressing VA RNAs, 30 genes were also
downregulated after transfection with pVAI and 26 were
inhibited after transfection with pmivaRNAI-138, sug-
gesting that mivaRNAI-138 could control the expression
of these genes also in infected cells. Besides, eight genes
were downregulated in pVA transfected cells but not in
WT adenovirus infected cells, indicating that they could
escape mivaRNA control during infection. Noticeably,
Figure 6. TIA-1 mRNA is a direct target of mivaRNAI-138.
(A) Schematic of Renilla luciferase mRNA with TIA-1 mivaRNAI-
138 target sequence (pRL-TIA-1) or with a matching seed
complementary mutated sequence (pRL-TIA-1Mut). mivaRNAI-138
binding to the RNA is indicated for clarity. (B) mivaRNAI-138
decreases expression of a Renilla luciferase reporter mRNA with
TIA-1 mivaRNAI-138 target sequences. HeLa cells were transfected
with the plasmids expressing the Renilla constructs shown in (A), and
a control plasmid or pVA, pVAI and pmivaRNAI-138 plasmids.
A plasmid expressing a Fireﬂy luciferase reporter was also
co-transfected as a control. Luciferase activity was evaluated at 48h
posttransfection. Renilla luciferase expression in control cells was set to
100% and the percentage of Renilla expression in all cases was
calculated accordingly. Error bars show standard deviations of three
diﬀerent experiments. Asterisk highlights signiﬁcant diﬀerences while ns
indicates non-signiﬁcant diﬀerences.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 757Figure 7. mivaRNAs downregulate the expression of several genes. Expression of each gene was evaluated by quantitative RT–PCR in cells infected
with wild-type or a VA mutant adenovirus at 12, 24, 48 and 72hpi (A) and in cells transfected with a control plasmid, pVA, pVAI or pmivaRNAI-
138 (B). Error bars show standard deviations of three diﬀerent measurements. Only representative genes are shown.
758 Nucleic Acids Research, 2010,Vol. 38,No. 3inhibitions were normally higher in infected cells than in
transfected cells expressing VA RNAs or mivaRNAs.
DISCUSSION
We have employed several methods to identify cellular
targets of adenoviral miRNAs: bioinformatics, proteomics
and genomics. Computer predictions using as input
50 mivaRNAI and 30 mivaRNAI-138, mivaRNAI-137
and mivaRNAII-138 retrieved a long list of putative
targets. Note that a diﬀerence in Dicer cleavage of only
1 nt yields two diﬀerent mivaRNAs, mivaRNAI-137 and
138, with a 1nt shift in the seed sequence. This results in
diﬀerent targets being regulated by miRNAs very similar
in sequence. This could also be observed for cellular
miRNAs and could theoretically be regulated.
Table 1. Expression analysis in cells expressing mivaRNAs
Probe Name Putative targets 12hpi 24hpi 48hpi 72hpi pVA pVAI pmiva
RNAI-138
Category
Hs00181599_m1 ADCY9 I-138; I-137; II-138 0.98 1.80 2.37 4.14 1.50 2.87 1.82 Signalling
Hs00388776_m1 ARHGEF7 I-138; I-137; II-138 1.05 1.39 2.81 3.31 1.72 1.77 1.92 Signalling
Hs00176747_m1 MAP3K3 I-138; I-137; II-138 1.46 2.31 3.63 5.51 2.71 3.91 1.93 Signalling
Hs00187940_m1 DUSP3 I-138(TS); I-137 1.60 2.33 3.53 6.10 2.02 4.70 1.65 Signalling
Hs00193642_m1 PPP1R3C I-138(TS); I-137 1.53 6.61 11.81 15.44 1.55 3.64 1.87 Signalling
Hs00743856_s1 PTP4A1 I-138; II-138 1.24 1.46 3.51 5.03 2.09 2.66 1.15 Signalling, growth
Hs00234259_m1 TGFBR3 I-138(TS); I-137; II-138 1.42 1.79 3.87 9.44 1.67 3.43 2.05 Growth, signalling
Hs00382690_m1 LY6K I-138; I-137 3.61 2.91 ND ND 3.08 8.76 2.69 Growth
Hs00277039_m1 CCND1 I-138; II-138 1.20 1.96 2.18 3.83 1.86 1.93 2.30 Growth
Hs00188949_m1 BNIP3L I-138; II-138 1.04 2.08 2.77 3.15 1.79 1.95 1.19 Proapoptotic
Hs00969291_m1 BNIP3 I-137 0.98 1.64 2.99 3.68 1.71 3.00 1.82 Proapoptotic
Hs00901425_m1 ETS1 I-138(TS); I-137 2.19 2.96 9.55 5.46 1.52 2.72 1.95 Transcription, growth
Hs00176209_m1 CDK8 I-138; I-137 1.49 1.99 3.12 7.77 1.58 1.94 1.67 Transcription, growth
Hs00794653_m1 RBPSUH I-138(TS); I-137; II-138 1.36 1.79 3.69 6.51 2.35 2.69 2.82 Transcription, recombination
Hs00363134_m1 PHF20 I-138; I-137; II-138 1.10 1.46 1.82 2.45 1.63 2.35 2.68 Transcription
Hs00212624_m1 TH1L I-138(TS) 1.03 1.32 2.46 6.04 1.58 2.27 2.56 Transcription
Hs00429643_m1 DAZAP2 I-138; I-137 1.11 1.58 2.60 5.15 2.68 7.71 2.06 RNA
Hs00389488_m1 MDN1 I-138; I-137; II-138 1.30 1.29 2.05 3.40 1.51 2.68 1.83 RNA
Hs00198069_m1 CUGBP1 I-137; II-138 1.45 2.27 4.14 5.50 1.85 3.47 2.14 RNA
Hs00287641_m1 QKI I-138; I-137; II-138 1.05 1.24 1.67 2.54 1.75 3.11 1.91 RNA
Hs00173159_m1 POLS I-138(TS); I-137 1.14 1.95 2.23 4.55 1.53 1.92 1.68 DNA repair
Hs00243513_m1 EXO1 I-137 1.35 1.42 3.40 6.14 2.32 5.17 3.17 DNA repair
Hs00854751_s1 UBE2N I-137 1.34 1.05 3.27 2.00 2.06 1.54 0.92 DNA repair
Hs00189460_m1 PHC2 I-138(TS); I-137; II-138 1.58 2.66 3.75 11.73 1.84 3.94 2.33 DNA
Hs00293359_m1 DOLPP1 I-138; II-138 1.33 1.43 2.17 2.72 1.66 2.03 1.51 Modiﬁcation
Hs00390363_m1 KIAA0528 I-138(TS) 1.03 1.51 5.59 4.12 1.90 2.28 1.53 UK
Hs00412280_m1 KIAA0182 I-138(TS); I-137; II-138 1.19 2.17 2.53 5.16 2.23 3.65 2.23 UK
Hs00376032_m1 C16orf63 I-138(TS) 1.12 1.23 2.80 3.74 2.23 2.15 1.57 UK
Hs00367486_m1 C1orf43 I-138(TS); I-137; II-138 1.17 2.37 3.55 7.00 1.98 2.67 1.36 UK
Hs00230651_m1 C9orf5 I-138(TS); II-138 1.09 1.38 2.19 3.25 1.76 3.71 1.90 UK
Hs00181213_m1 IGFBP5 I-138; I-137; II-138 0.39 0.65 0.61 1.37 1.62 3.85 1.83
Hs00272413_m1 RAD51AP1 I-138; I-137 0.96 1.24 2.41 1.57 2.37 2.53 1.91
Hs00757386_s1 ARL5A II-138 1.06 1.18 1.76 1.97 2.47 1.93 1.52
Hs00209047_m1 CEP164 I-138; II-138 1.28 1.65 1.35 0.44 1.80 3.25 2.53
Hs00216375_m1 IPO9 I-137; II-138 1.27 1.41 1.10 1.97 1.61 3.03 1.80
Hs00757716_m1 CUL4A I-138; II-138 1.06 1.92 1.60 1.74 1.67 2.08 1.21
Hs00245657_m1 HNRPDL I-137 1.15 1.22 1.52 1.60 1.20 1.99 1.25
Hs00830558_g1 CHES1 I-138; I-137; II-138 1.33 1.13 1.01 1.69 1.80 2.23 1.21
Hs00392822_m1 SETD1B I-138; I-137; II-138 1.71 1.58 3.94 10.20 1.15 0.93 1.26 Chrom remodeling
Hs01030716_m1 PRDM2 I-138(TS); I-137; II-138 1.58 1.40 3.28 2.46 1.08 1.08 1.13 Chrom remodeling
Hs00428515_g1 MAT2A II-138 0.61 1.32 2.33 2.80 1.06 0.94 1.05 Metabolism
Hs00265885_g1 EEF1A1 II-138 0.86 0.97 0.86 0.84 1.35 1.06 1.07
Hs00228436_m1 CHD9 II-138 0.87 1.34 2.06 1.09 1.25 0.84 1.16
Hs00542737_m1 SHPRH II-138 0.72 1.23 2.12 1.90 1.04 1.04 1.11
Hs99999906_m1 PGK1 II-138 0.73 0.78 0.98 1.45 0.65 1.18 0.90
Hs00325656_m1 NFIA II-138 1.08 1.00 1.14 1.77 0.98 1.05 1.16
Hs00187953_m1 EIF2S1 I-137; II-138 0.75 0.74 1.39 1.67 1.02 0.75 1.11
Hs00831673_gH EIF2S3 I-138 0.94 0.86 1.10 1.13 0.66 0.91 1.20
Hs00199471_m1 SFRS1 1.01 1.08 1.56 1.70 1.16 1.00 1.22
Expression of each gene was evaluated by quantitative RT–PCR in cells transfected with a control plasmid, pVA, pVA1 or pmivaRNAI-138 and in
cells infected with wild-type or a VA mutant adenovirus at 12, 24, 48 and 72hpi. Fold inhibition is indicated for each condition and was calculated
by the ratio of expression levels in control cells versus levels in mivaRNA expressing cells. The probe used in the PCR, the putative targets and a
functional category are also indicated for each gene. When fold inhibition was higher than 1.5 at 48hpi and higher than 2.0 at 72hpi (marked in
bold), the gene was considered to show decreased expression in cells infected with the mivaRNA expressing virus. ND indicates that the expression of
the gene was undetectable in infected cells expressing VA RNAs. TS indicates that the gene was also identiﬁed by TargetScan. UK denotes unknown
function.
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of mivaRNAs did not allow identiﬁcation of target genes.
The diﬀerences observed in the proteome may have
resulted from secondary eﬀects of VA RNA expression.
Real targets may have been diﬃcult to identify by
proteomics due to charge, low abundance or few
diﬀerences in expression in the presence and absence of
the miRNA regulator. Modiﬁcations to the proteomics
protocol could have been applied to increase the number
of proteins detected and ease quantiﬁcation (51).
Alternatively, we decided to analyze the impact of VA
RNA expression on mRNA accumulation with human
whole genome microarrays. The combination of the
results obtained with the microarray analysis and
bioinformatic searches allowed us to obtain a short list
of VA RNA-downregulated genes with putative target
sequences (Figure 2, Supplementary Table S3).
VA RNA overexpression can block Dicer and Exp5
(17,21). Dicer and Exp5 inhibition should lead to a
decrease in cellular miRNAs and, therefore, an increase
in miRNA-targets. However, completion of this cascade
should take several days, as cellular miRNAs are very
stable (33). Also, overexpression of adenoviral miRNAs
should saturate RISC (17). However, we found no
upregulation of any well-characterized miRNA targets,
such as BCL2, PDCD4, CDKN2A or PTEN, which are
regulated by miRNAs highly expressed in HeLa cells
(52–55). It may be that in our experimental conditions,
viral miRNA production was not high enough to
saturate RISC.
VA RNA decreases mRNA levels of 462 genes. This
could be caused by decreased transcription and/or
increased decay. Transcription of several downregulated
genes is controlled by Ets-1 and Elk, which decrease in the
presence of VA RNA. VA RNAs are processed to several
viral miRNAs that could activate decay of target mRNAs.
The major miRNAs are mivaRNAI-137, mivaRNAI-138
and mivaRNAII-138 (28). Other viral miRNAs are also
produced from VA RNAs to lower levels, and therefore
should have a lower capacity for gene regulation (23,28).
This is the case of 50 mivaRNAI, which has been shown to
have a lower impact than 30mivaRNAI in the inhibition of
genes with complementary sequences and on virus
functionality (23). Also, we found no ‘antitarget signa-
ture’, a relative decrease in mRNAs upregulated by VA
RNA with 50 mivaRNAI targets (Figure 2A). The
antitarget signature is nicely observed for the major
mivaRNAs (Figure 2).
The results show that out of 462 downregulated genes,
305 have seed complementary sequences to major
mivaRNAs and 172 have more than 1 putative target
for major mivaRNAs in all possible combinations
(Supplementary Table S3). Fifty genes were further
evaluated and eight showed decreased expression only in
cells expressing VA RNA upon transfection, indicating
that they could escape VA RNA or mivaRNA control
during infection. Regulation of miRNA-mediated inhibi-
tion has been already described for some cellular miRNA
targets. Thirty-one of the evaluated genes showed
decreased expression when VA RNA expression was
achieved by transfection or infection (Figure 7, Table 1).
Five of them have unknown functions. Seven are related
to cell signalling (ADCY9, ARHGEF7, MAP3K3,
DUSP3, PPP1R3C, PTP4A1 and TGFBR3) and nine to
cell growth and apoptosis (PTP4A1, TGFBR3, LY6K,
CCND1, BNIP3L, BNIP3, TIA-1, ETS1 and CDK8).
Nine are related to DNA and involved in transcription
or DNA repair (ETS1, CDK8, RBPSUH, PHF20,
TH1L, PHC2, POLS, EXO1 and UBE2N), and ﬁve are
involved in RNA metabolism (DAZAP2, MDN1,
CUGBP1, QKI and TIA1) (Table 1). Interestingly, other
authors have already shown that DNA repair and
apoptosis are inhibited in adenovirus-infected cells.
Moreover, miRNAs derived from other viruses, such as
KSHV and EBV, have been shown to target proapoptotic
genes. Inhibitions are normally higher in infected cells
than in transfected cells expressing VA RNAs or
mivaRNAs. This could reﬂect that infected cells saturate
the RISC machinery with viral mivaRNAs so the RISC
complex could be more eﬃcient in silencing mivaRNA
target genes. Alternatively, there could be other
mechanisms that cause decreased expression of these
genes in infected cells, as seems to be the case for
SETD1B, PRDM2 and MAT2A. Some genes show
inhibitions higher than average also in transfected cells
expressing mivaRNAI-138, indicating that those genes
could have several target sites which act cooperatively.
Thirty-two out of the 50 genes evaluated are
downregulated in cells expressing mivaRNAI-138. Out
of the 15 genes identiﬁed by TargetScan and analyzed
further, 13 were downregulated in cells expressing
mivaRNAI-138. This highlights the eﬃcacy of the predic-
tion program. Small scale studies will be required to deter-
mine whether the genes downregulated in mivaRNAI-138
expressing cells are direct targets of this miRNA and to
evaluate their eﬀects in adenoviral infections.
The list of genes downregulated by VA RNA shows a
statistically signiﬁcantly increase of genes related to RNA
binding, splicing and translation (Supplementary Table
S2). It is unclear to us why VA RNA expression decreases
many genes related to RNA metabolism. Also, most of
these genes do not contain seed-complementary sequences
to major mivaRNAs. One exception is TIA-1, an RNA
binding protein related to splicing and translation. TIA-1
has a good mivaRNAI-138 target sequence according to
several published parameters (Figure 3 and see the Results
section) (11). We were surprised to see that mivaRNAI-
138 targets a region which is also predicted to be
seed-complementary to two other cellular miRNAs
(Figure 3B). We speculate that 30UTR sequences capable
of being regulated by miRNAs could be rare, as they need
to be accessible. Therefore, when a virus develops func-
tional miRNAs to control cellular gene expression, there
could be a high possibility that they target similar
sequences than cellular miRNAs. In fact, a viral miRNA
with the same seed sequence as a cellular miRNA has been
described (56,57). Thus, the presence of cellular miRNA
targets could be a beneﬁt in an algorithm for the predic-
tion of viral miRNA targets. A disadvantage of sharing
target sequences is that there could be competition
between cellular and viral miRNAs. This should not be
760 Nucleic Acids Research, 2010,Vol. 38,No. 3a problem in the case of adenovirus as major mivaRNAs
are expressed to high levels.
TIA-1 mRNA is a direct target of mivaRNAI-138. TIA-
1 protein and mRNA are downregulated in transfected
cells that express mivaRNAI-138 or in cells infected with
an adenovirus that expresses functional mivaRNAI (v 4
and 5). Our results suggest that mivaRNAI-138 inhibits
translation and activates RNA decay of TIA-1 mRNA.
mivaRNAI-138 is detected at 12hpi and accumulates as
infection proceeds (23). A decrease in TIA-1 protein was
ﬁrst detected 24hpi (v 5) and later, at 48hpi, we observe a
downregulation of TIA-1 mRNA (Figure 4). We also used
a reporter assay to deﬁne mivaRNAI-138 target in TIA-1
and to prove that mivaRNAI-138 binds directly to this
target. Note that this region is also a putative target for
hsa-miR337-5p and hsa-miR-30, but these miRNAs are
poorly expressed in 293 and HeLa cells, so they should
not control the expression of the Renilla reporters
(compare Mock bars in Figure 6B).
mivaRNAI-138 has been only characterized in
adenovirus family C (Adenovirus 2 and 5). Members
from other subgenera (A, B, D, E or F) also express VA
RNAs with a terminal stem that could be cleaved by
Dicer. However, the sequence and the structure of the
terminal stem is diﬀerent in diﬀerent families, including
bulges and G:U wobbles at diﬀerent positions that could
aﬀect Dicer cleavage. Therefore it is diﬃcult to predict
whether Dicer cleavage could occur at the same position
in VA RNAs from all families. Assuming Dicer cleaves at
identical position or allowing a diﬀerence in cleavage of 1
nucleotide, we have found seed complementary sequences
in human TIA-1 mRNA from putative mivaRNA-138s
derived from all human adenovirus subgenera (data not
shown). Interestingly, several seed complementary
sequences from putative mivaRNA-138s derived from
simian adenovirus have been found in the 30UTR of
TIA-1 mRNA from macaca mulatta (data not shown).
This suggests that VA RNAs from diﬀerent adenovirus
could produce mivaRNA-138s with diﬀerent sequences
that also target TIA-1.
TIA-1 is a well-characterized factor that activates
apoptosis by controlling the RNA metabolism of some
mRNAs that encode for proapoptotic molecules (58).
We hypothesized that adenovirus infection could
proceed favorably with decreased TIA-1 and, therefore,
in a less apoptotic environment. However, none of the
experiments performed so far have demonstrated this
hypothesis (data not shown). TIA-1 binds to U rich
sequences to control RNA metabolism by increasing
splicing or by blocking translation (49, 59–61). Several
of the adenoviral mRNAs contain putative U rich TIA-1
binding sites in introns or 30UTRs. Further studies will be
required to address whether TIA-1 can control expression
of adenoviral genes. In fact, functional mivaRNAIs are
important for adenovirus production, as cells with
antagomir-blocked mivaRNAIs produce lower viral
titers (23). Therefore inhibition of TIA-1 or other
mivaRNAI targets could be relevant for virus production.
We cannot exclude that mivaRNA control of many of
these genes at the same time could ﬁne tune the expression
pattern in the cell to one that is more advantageous for
viral growth.
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